Overview

Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their normal standard of care. This study assesses the percentage of patients who achieve LDL-C target goals and also evaluates the patient compliance to treatment.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe
Fenofibrate